BriSTAR Immunotech
China - BeijingBiotechnology
Focus: BriSTAR Immunotech is a Beijing-based cell therapy biotechnology company founded in 2023, focused on developing STAR-T cell therapies for hematologic malignancies. The company operates as an early-stage biotech with a single Phase 1 program and no commercial products.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Open Jobs
0
About BriSTAR Immunotech
AI assessmentNot HiringNo open roles listed right now. Follow BriSTAR Immunotech to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from BriSTAR Immunotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LILRB4 STAR-T cells
Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic LeukemiaClinical Trials (1)
NCT05548088LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML
Phase 1Help build intelligence for BriSTAR Immunotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.